The FDA database lists a supplement dated 14 October 2026 to biologics licence application 103795 for etanercept (Enbrel), held by Immunex. Etanercept is a TNF inhibitor used in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and other conditions.
The record does not describe the change. Supplements to a long-established biologic licence most often concern manufacturing, labelling or presentation rather than a new indication or safety finding.
No safety communication accompanies this record, and nothing in it changes how etanercept or its biosimilars are prescribed. Availability and approvals in India are set by CDSCO.
- This is an FDA supplement to the etanercept licence, not a new indication.
- The record does not describe what changed.
- No safety warning accompanies it.
- Prescribing of etanercept and its biosimilars is unchanged.
Why it matters
It is a routine licence update with no clinical signal.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free